66 results about "Allogeneic graft" patented technology

An implant composed substantially of cortical bone is provided for use in cervical Smith-Robinson vertebral fusion procedures. The implant is derived from allograft or autograft cortical bone sources, is machined to form a symmetrically or asymmetrically shaped (e.g. a substantially "D"-shaped) implant having a canal running therethrough according to methods of this invention, and inserted into the space between adjacent cervical vertebrae to provide support and induce fusion of the adjacent vertebrae. Osteogenic, osteoinductive or osteoconductive materials may be packed into the canal of the implant to expedite vertebral fusion and to allow autologous bony ingrowth.

A method of treating avascular necrosis (“AVN”) comprising administering one or more osteoinductive formulations to the site of AVN disease progression. The method involves the combination of a core decompression technique, followed by the introduction of one or more osteoinductive formulations into the decompression core, and concluding with capping of the lateral aspect of the decompression core with a femoral core cap. The osteoinductive formulations of the invention comprise one or more osteoinductive agents and suitable carrier molecules. The femoral core cap retains the osteoinductive formulation within the decompression core, thereby preventing leakage of the osteoinductive formulation from the decompression core. The method of the invention optionally comprises introduction of autograft or allograft with the osteoinductive formulations of the invention. The method of the invention further optionally comprises incorporation of sustained release compositions to provide extended periods of osteogenesis.

The present technology is related to the field of sterilization and decellularization of allografts or xenografts, specifically to processes that achieve effective removal of the cells contained within a vascular tissue matrix and an effective reduction in potential harmful organisms to create grafts suitable for human implantation. In some embodiments, vascular grafts, vascular tissue and/or blood vessels are contacted with cleaning solution under conditions suitable conditions to reduce immune reaction in patients. More specifically, the present technology is directed to sterilization and decellularization of vascular grafts.

In some embodiments, a method to detect acute rejection in allograft from is described. In some embodiments, a method to anticipate an episode of acute rejection in allografts is also described. In some embodiments, a kit for detecting or predicting acute transplant rejection of a transplanted organ is described.

The present invention relates, generally, to methods and compositions for allogeneic transplantation. More particularly, the invention relates to the use of alloreactive natural killer cells in order to enhance the efficacy and/or safety of allogeneic grafts in human subjects. The invention allows to increase the engraftment of an allogeneic grafts, even in myelo-reductive conditioning, to protect against GVHD and/or to eradicate malignant cells. The invention is particularly suited in allogeneic hematopoietic transplantations, particularly bone marrow transplantations.

This invention provides a method of generating antigen specific allospecific human-suppressor CD8+CD28− T cells. This invention also provides a method of generating xenospecific human suppressor CD8+CD28− T cells. This invention further provides a method of generating allopeptide antigen specific human suppressor CD8+CD28− T cells. Methods of treatment for, reduction of risk of rejection of allografts and xenografts and autoimmune diseases using the human suppressor CD8+CD28− T cells so produced are also provides, as are methods of preventing rejection and autoimmune diseases, and vaccines comprising the produced suppressor T cells. Methods of diagnosis to determine whether a level of immuno-suppressant therapy requires a reduction are provided.

The invention provides agonistic TNFR2 antibodies and antigen-binding fragments thereof and encompasses the use of these antibodies as therapeutics to promote the proliferation of regulatory T cells (T-reg) for the treatment of immunological diseases. Antibodies of the invention can be used to potentiate the T-reg-mediated deactivation of self- and allergen-reactive T- and B-eases. Antibodies and can thus be used to treat a wide variety of indications, including autoimmune diseases, allergic reactions, asthma, graft-versus-host disease, and allograft rejection, among others.

A bandage for covering a wound treated with an allograft can include a liquid permeable skin adherent layer having a wound facing surface with an adhesive thereon for adhering to skin proximate the wound. A compressible support section can be supported by the skin adherent layer for maintaining the allograft in place on the wound, and an absorbent section can be positioned over the compressible support section. The absorbent section can be comprised of a liquid absorbent material and can aid in keeping the allograft hydrated. The compressible support section can be positioned intermediate the skin adherent layer and the absorbent section. A liquid permeable covering layer can be positioned over the absorbent section, and attached to the skin adherent layer.

The invention relates to a method for producing a tissue matrix for an allotransplantation or a xenotransplantation, according to which, once a biological tissue has been obtained, said tissue is classified, said tissue is treated and the tissue matrix produced is conditioned, all of said steps being implemented in an automated manner inside the same 'classified' reactor. The invention also relates to the reactor allowing the implementation of the method of the invention.